

SPEAKER

Jelle Wesseling

Department of Pathology & Division
of Molecular Pathology
Netherlands Cancer Institute,
Amsterdam, The Netherlands



Ductal Carcinoma in Situ: When cancer isn't really cancer

Date: Tuesday Oct 15th – **Time:** 15:00 CEST

 [Link to Zoom](#)

Ductal carcinoma in situ (DCIS) now represents 25% of all screen-detected so-called 'breast cancers'. Yet, most DCIS lesions will never progress to breast cancer. Uncertainty as to which DCIS lesions may progress drives massive overtreatment of this often harmless disease. In this lecture, we will discuss how we unravel DCIS biology, identify biomarkers for DCIS progression risk, and perform clinical research, aiming to prevent the burden of invasive but needless treatment of women diagnosed with harmless DCIS.

Jelle Wesseling is a consultant breast pathologist and senior PI at the Netherlands Cancer Institute and professor of breast pathology at Leiden University Medical Center. He leads the Cancer Grand Challenge PRECISION initiative aiming to unravel DCIS biology and diminish DCIS overtreatment and the Dutch Direct-DCIS project for AI-based risk prediction in DCIS.

Hosted by:

NETHERLANDS
CANCER
INSTITUTE



ANTONI VAN LEEUWENHOEK